Anika Therapeutics (ANIK) Income towards Parent Company (2010 - 2025)

Anika Therapeutics (ANIK) has 16 years of Income towards Parent Company data on file, last reported at -$1.5 million in Q4 2025.

• On a quarterly basis, Income towards Parent Company rose 92.21% year-over-year to -$1.5 million in Q4 2025; TTM through Mar 2026 was $14000.0, a 100.03% increase from a year earlier, with the FY2025 full-year figure at -$901000.0, up 98.11% from the prior year.
• Income towards Parent Company for Q4 2025 stood at -$1.5 million, down from $846000.0 in the prior quarter.
• Over the last five years, Income towards Parent Company for ANIK reached as high as $15.5 million in Q4 2023 and fell as low as -$28.1 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$2.6 million across 5 years, with a median of -$2.0 million in 2024.
• On a YoY basis, Income towards Parent Company climbed as much as 213.4% in 2022 and fell as far as 856.34% in 2022.
• Year by year, Income towards Parent Company stood at -$10.7 million in 2021, then soared by 213.4% to $12.2 million in 2022, then rose by 27.46% to $15.5 million in 2023, then sank by 225.08% to -$19.4 million in 2024, then soared by 92.21% to -$1.5 million in 2025.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$1.5 million in Q4 2025, $846000.0 in Q3 2025, and $677000.0 in Q2 2025.